Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: final results of the LYRA study. Issue 10 (24th August 2022)

• Record Type: Journal Article
• Authors: Yimer, Habte; Melear, Jason; Faber, Edward; Bensinger, William I.; Burke, John M.; Narang, Mohit; Stevens, Don; Gray, Kathleen S.; Lutska, Yana; Bobba, Padma; Qi, Keqin; Hoehn, Daniela; Qi, Ming; Lin, Thomas S.; Rifkin, Robert M.
• Is Part Of: Leukemia & lymphoma. Volume 63:Issue 10(2022)
• Page Start: 2383
• Page End: 2392
• Publication Date: 2022-08-24
• Subjects: Daratumumab -- newly diagnosed multiple myeloma -- CyBorD; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2022.2076847
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: In the primary analysis of LYRA, daratumumab + cyclophosphamide/bortezomib/dexamethasone (DARA + CyBorD) was effective and well tolerated in newly diagnosed multiple myeloma (NDMM) and relapsed multiple myeloma (RMM). We report the final analysis of LYRA (median months of follow-up: NDMM, 35.7; RMM, 35.3) after all patients completed study therapy, were followed for 36 months, or discontinued. Patients received DARA + CyBorD induction, autologous stem cell transplant (if eligible), and 12 months of daratumumab maintenance. Eighty-seven NDMM patients enrolled, 39 underwent transplant, and 63 completed maintenance. Rates of complete response or better were 48.7% and 29.8% for NDMM transplant and NDMM non-transplant patients, respectively, and 36-month progression-free survival rates were 69.3% and 72.6%. Grade 3/4 treatment-emergent adverse events occurred in 61.6% of NDMM patients. Efficacy and safety data are also reported for the smaller RMM cohort ( n = 14). DARA + CyBorD followed by daratumumab maintenance was well tolerated and achieved deep, durable responses in NDMM and RMM.